Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.
Denis Sauré,Miguel O'Ryan,Juan Pablo Torres,Marcela Zuniga,Emilio Santelices,Leonardo J. Basso +5 more
TLDR
In this article, the authors compared the proportion of individuals testing positive for anti-SARS-CoV-2 IgG across sites by week since vaccination between recipients of CoronaVac and BNT162b2.Citations
More filters
Journal ArticleDOI
Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study
A. Jara,Eduardo A. Undurraga,José R. Zubizarreta,Cecilia Gonzalez,Alejandra Pizarro,Johanna Acevedo,Katherinne Leo,Fabio Paredes,Tomás Bralic,V. Vergara,Marcelo Mosso,Francisco Leon,Ignacio Parot,Paulina Leighton,P. Suárez,J. C. Ríos,Heriberto E. García-Escorza,Rafael Araos +17 more
TL;DR: The results suggest that a homologous or heterologous booster dose for individuals with a complete primary vaccination schedule with CoronaVac provides a high level of protection against COVID-19, including severe disease and death.
Journal ArticleDOI
Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil
Thiago Cerqueira-Silva,Srinivasa Vittal Katikireddi,V. de Araujo Oliveira,Renzo J Flores-Ortiz,Juracy Bertoldo dos Santos Junior,Enny S. Paixão,Chris Robertson,Gerson Oliveira Penna,Guilherme Loureiro Werneck,Mauricio Lima Barreto,Neil Pearce,Aziz Sheikh,Manoel Barral-Netto,Viviane Boaventura +13 more
TL;DR: In this article , a test-negative design study involving almost 14 million people was conducted to estimate the effectiveness of CoronaVac over time and BNT162b2 booster vaccination against RT-PCR-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and severe COVID-19 outcomes (hospitalization or death).
Journal ArticleDOI
Efficacy and safety of Paxlovid for COVID-19:a meta-analysis
Qian Zheng,Pengfei Ma,Ming-Wei Wang,Yongran Chen,Mengyun Zhou,L. Ye,Zhan-Hui Feng,Chun-Lin Zhang +7 more
TL;DR: Wang et al. as discussed by the authors performed a meta-analysis of Paxlovid in patients with COVID-19 and reported a case of COVID19 rebound in a severe COVID 19 patient during long term (20 days) treatment.
Journal ArticleDOI
Contribution of low population immunity to the severe Omicron BA.2 outbreak in Hong Kong
Lin-Lei Chen,Syed Muhammad Umer Abdullah,Wan-Mui Chan,Brian Chun-Yuan Chan,Jonathan Daniel Ip,Allen Wing-Ho Chu,Lu Lu,Xiaojuan Zhang,Yan Zhao,Vivien W M Chuang,Albert Ka-Wing Au,Vincent C.C. Cheng,Siddharth Sridhar,Kwok-Yung Yuen,Ivan Hung,Kwok-Hung Chan,Kelvin K. W. To +16 more
TL;DR: In this paper , a seroprevalence study using sera collected from January to December 2021 shows a very low prevalence of neutralizing antibodies (NAb) against ancestral virus among older adults.
Journal ArticleDOI
Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study
TL;DR: Given the low antibody titres and fast decline in the CoronaVac group in individuals 60 years or older, more potent vaccine options could be considered as the primary vaccination or booster dose in these high-risk populations to sustain antibody responses for longer.
References
More filters
Journal ArticleDOI
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
Fernando P. Polack,Stephen J. Thomas,Nicholas Kitchin,Judith Absalon,Alejandra Gurtman,Stephen Lockhart,John L. Perez,Gonzalo Pérez Marc,Edson D. Moreira,Cristiano Zerbini,Ruth Bailey,Kena A. Swanson,Satrajit Roychoudhury,Kenneth Koury,Ping Li,Warren Kalina,David A. Cooper,Robert W. Frenck,Laura L. Hammitt,Özlem Türeci,Haylene Nell,Axel Schaefer,Serhat Ünal,Dina B. Tresnan,Susan Mather,Philip R. Dormitzer,Ugur Sahin,Kathrin U. Jansen,William C. Gruber +28 more
TL;DR: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older and safety over a median of 2 months was similar to that of other viral vaccines.
Journal ArticleDOI
Julia: A Fresh Approach to Numerical Computing
TL;DR: The Julia programming language as mentioned in this paper combines expertise from the diverse fields of computer science and computational science to create a new approach to numerical computing, which is designed to be easy and fast and questions notions generally held to be “laws of nature" by practitioners of numerical computing.
Journal ArticleDOI
Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection.
David S. Khoury,Deborah Cromer,Arnold Reynaldi,Timothy E. Schlub,Timothy E. Schlub,Adam K. Wheatley,Jennifer A Juno,Kanta Subbarao,Stephen J. Kent,Stephen J. Kent,Stephen J. Kent,James A. Triccas,Miles P. Davenport +12 more
TL;DR: It is shown that neutralization level is highly predictive of immune protection, and an evidence-based model of SARS-CoV-2 immune protection that will assist in developing vaccine strategies to control the future trajectory of the pandemic is provided.
Journal ArticleDOI
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting.
Noa Dagan,Noam Barda,Noam Barda,Noam Barda,Eldad Kepten,Oren Miron,Oren Miron,Shay Perchik,Mark A. Katz,Mark A. Katz,Mark A. Katz,Miguel A. Hernán,Marc Lipsitch,Ben Y. Reis,Ran D. Balicer,Ran D. Balicer +15 more
TL;DR: This study in a nationwide mass vaccination setting suggests that the BNT162b2 mRNA vaccine is effective for a wide range of Covid-19–related outcomes, a finding consistent with that of the randomized trial.
Journal ArticleDOI
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
Yanjun Zhang,Gang Zeng,Hongxing Pan,Changgui Li,Yaling Hu,Kai Chu,Weixiao Han,Zhen Chen,Rong Tang,Weidong Yin,Xin Chen,Yuansheng Hu,Xiao-Yong Liu,Cong-Bing Jiang,Jingxin Li,Minnan Yang,Yan Song,Xiangxi Wang,Qiang Gao,Fengcai Zhu +19 more
TL;DR: The primary safety endpoint was adverse reactions within 28 days after injection in all participants who were given at least one dose of study drug (safety population).
Related Papers (5)
BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
Yaniv Lustig,Yaniv Lustig,Einav Sapir,Einav Sapir,Gili Regev-Yochay,Gili Regev-Yochay,Carmit Cohen,Ronen Fluss,Liraz Olmer,Victoria Indenbaum,Michal Mandelboim,Michal Mandelboim,Ram Doolman,Sharon Amit,Ella Mendelson,Ella Mendelson,Arnona Ziv,Amit Huppert,Carmit Rubin,Laurence S. Freedman,Yitshak Kreiss,Yitshak Kreiss +21 more
Spike-antibody responses following first and second doses of ChAdOx1 and BNT162b2 vaccines by age, gender, and clinical factors - a prospective community cohort study (Virus Watch)
Madhumita Shrotri,Madhumita Shrotri,Ellen Fragaszy,Ellen Fragaszy,Cyril Geismar,Vincent Nguyen,Sarah Beale,Isobel Braithwaite,Thomas Byrne,Wing Lam Erica Fong,Jana Kovar,Annalan M D Navaratnam,Parth Patel,Anna Aryee,Jamie Lopez Bernal,Anne M Johnson,Alison Rodger,Andrew Hayward,Robert W Aldridge +18 more